AbbVie (ABBV) Declares $0.51 Quarterly Dividend; 3% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Receptos (RCPT) Will Be Patient on Takeover, Leerink Partners Says; Insider Sales Not a Tell
June 17, 2015 5:04 PM EDTIn a report on Receptos (NASDAQ: RCPT) after the close, Leerink Partners analyst Joseph Schwartz noted weakness in the stock today followed a blog post which highlighted the Form 4 filed by LLY Ventures Partner last evening (6/16) disclosing sale of ~20% stake (equivalent of ~$40MM), which he said could be indirectly viewed as management lack of willingness for a potential deal in the near future. Schwartz does not share this view and continues to believe that mgmt. is... More
UPDATE: Piper Jaffray Starts Abbvie (ABBV) at Overweight
June 16, 2015 4:36 PM EDT(Updated - June 17, 2015 7:54 AM EDT)
Piper Jaffray initiated coverage on Abbvie (NYSE: ABBV) with an Overweight rating and a price target of $77.00.
Analyst Richard Purkiss commented, "we see AbbVie as a highly defensive near-term growth story with a differentiated dividend outlook. Near-term... More
